>Antigens & Antibodies for Diagnostic Kit Development
The diagnosis of SARS-CoV-2 infection is central to the management of viral transmission. To affirm infection, precise diagnostic tests that detect viral nucleic acids, viral antigens or serological antibodies are required. Compared with nucleic acid tests, antigen or serological antibody tests are set up for rapid screening and instant detection for their convenience to perform and the short time required for generating test results.
Rapid and accurate viral detection is the starting point to contain the COVID-19 pandemic.
Antigen tests that detect the presence of virus in nasopharyngeal fluids are used to prevent infectious spread between persons and communities. The challenge of diagnosis has upgraded due to the increasing number of cases of asymptomatic infection, which may aid inadvertent spread of the virus to others. Therefore, high test sensitivity and specificity are required to minimize the chance of false-negative test results.
Inducing immunity against SARS-CoV-2 is the next frontier for COVID-19 control.
Serological antibody tests as the complement of virus detection can indicate past infection. In these tests, IgG, IgM and neutralizing antibodies are detected qualitatively by enzyme-linked immunosorbent assay (ELISA). Serological antibody tests are helpful to assess protection against subsequent viral exposure, trace contact, and perform broad epidemiological evaluations.
The war against SARS-CoV-2 has changed because of mutants.
From D614G to Delta and Lambda, mutants have replaced the wild type and changed the war against COVID-19. Consequently, effectiveness of the existing detection methods, which were developed based on the parental type of the virus, becomes a significant question. Minimizing off-target effects becomes the key to block the spread of viral mutants.
TThe sensitivity and specificity of diagnostic kits significantly depend on the quality of the antigen or antibody reagents. To support the development of SARS-CoV-2 diagnostic tools, ACROBiosystems supply a collection of high-quality mutants-specific antigens and antibody reagents with verified high purity, bioactivity and batch-to-batch consistency.
The matched SARS-CoV-2 S/N antibody pairs are specifically designed for antigen detection kit development, which are suitable for a diverse set of applications, including ELISA, Chemiluminescence immunoassay (CLIA), Gold Immunochromatography Assay (GICA), etc. These antibody pairs are characterized with high sensitivity, specificity and consistency for antigen detection of both the wild type antigen and VOC mutants.
|Category||Cat. No.||Species||Product Description|
|Nucleocapsid protein||NUN-CH14||Human||Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS95) (MALS verified)|
|NUN-CH15||Mouse||Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) (MALS verified)|
|NUN-BM272||Mouse||Biotinylated Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) (MALS verified)|
|NUN-S46||Mouse||Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (Trehalose free)|
|NUN-S47||Mouse||Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) (Trehalose free)|
|S1 protein||S1N-M12A1||Mouse||Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122) (Trehalose free)HOT||Inquiry|
|S1N-M13A1||Mouse||Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM130) (Trehalose free)HOT||Inquiry|
|S1N-S58||Mouse||Anti-SARS-CoV-2 Spike S1 Antibody, Mouse IgG1 (AS58) (Trehalose free)||Inquiry|
These antibodies were recommended for antigen detection by double antibody sandwich.
>>> Virus lysis buffer (Cat. No. LY-14) is available for antigen detection kit development.
>>> If you have any bulk order inquiry, please feel free to click here.
The two antibodies (NUN-CH14/NUN-CH15) bind at different epitopes of the SARS-CoV-2 nucleocapsid protein, significantly improving the efficiency of antigen detection. The antibody pairs can detect the inactivated virus sample at 1:38400 dilution ratio, as well as the Delta variant and wild type antigens at both 0.195 ng/mL.
The detection results of the inactivated virus sample at gradient dilution ratio
The detection results of the Delta and wild type antigens at gradient concentrations.
ACROBiosystems provide Spike and Nucleocapsid antigens and antibodies specifically designed for IgG/IgM antibody titer test development and compatible with multiple platforms, i.e. ELISA, Chemiluminescence immunoassay (CLIA), Gold Immunochromatography Assay (GICA). The products below are available in bulk order or customized size.
Antigens for diagnostics
Positive control antibodies
|Molecule||Cat. No.||Host||Tag||Recommended application||Recommended method|
|S protein||SPN-C52H7||HEK293||His Tag||Detect IgG/IgM by capture method||ELISA|
|S1 protein||S1N-C52H2||HEK293||His Tag||Detect IgG/IgM by capture method||Inquiry|
|S1N-C82E9||HEK293||His,Avi tag™||Detect IgG/IgM by capture method||Inquiry|
|S2 protein||S2N-C52H2||HEK293||His Tag||Detect IgG/IgM by capture method||Inquiry|
|RBD protein||SPD-C52H1||HEK293||His Tag||Detect total antibodies by double antigen sandwich method (detection)||Inquiry|
|SPD-C52H2||HEK293||His Tag||Detect IgG/IgM by capture method||Inquiry|
|SPD-C5251||HEK293||Mouse Fc Tag||Detect total antibodies by double antigen sandwich method (capture)||Inquiry|
|SPD-C82E8||HEK293||His,Avi tag™||Detect IgG/IgM by capture method||Inquiry|
|Nucleocapsid protein||NUN-C5221||HEK293||His Tag||Detect IgG/IgM by capture method||Inquiry|
|NUN-C51H2||E.coli||His Tag||Detect IgG/IgM by capture method||Inquiry|
|Cat. No.||Species||Product Description||Subtype||Molecule|
|S1N-M122||Mouse||Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb (AM122)||Human IgG1||S protein RBD||Inquiry|
|SPD-M180||Human||Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody (AM180)||Human IgG1||S protein RBD||Inquiry|
|SAD-S35||Human||Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody (AS35)||Human IgG1||S protein RBD||Inquiry|
|SPD-M128||Mouse||Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb (AM128)||Human IgG1||S protein RBD||Inquiry|
|S1N-M130||Mouse||Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb (AM130)||Human IgG1||S protein RBD||Inquiry|
|SPD-M121||Mouse||Anti-SARS-CoV-2 Spike NTD Neutralizing Antibody, Chimeric mAb (AM121)||Human IgG1||S1 protein NTD||Inquiry|
|SPD-M162||Mouse||Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb (AM122)||Human IgM||S protein RBD||Inquiry|
|S2N-S86||Human||Anti-SARS-CoV-2 Spike S2 Antibody (AS86)||Human IgG4||S2 protein||Inquiry|
>>> If you have any bulk order inquiry, please feel free to click here.
>>> If you have any custom inquiries or suggestions for SARS-CoV-2 (COVID-19) related products, please click here.
Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 NP Antibody, Rabbit MAb (CLN27) with a linear range of 0.02-0.3 ng/mL (QC tested).
Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat. No. S1N-M122) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7 | Alpha, B.1.351 | Beta, P.1 | Gamma, B.1.617.1 | Kappa, B.1.617.2 | Delta mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat. No. S1N-M122) has high batch-to-batch consistency (%RSD<5%)
>>> Any custom requests, suggestions or feedback are welcome.Click here.
This web search service is supported by Google Inc.